Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN85,5485,551,69
Msft-0,22
Nokia4,4114,466-0,23
IBM-0,70
Mercedes-Benz Group AG50,7450,761,98
PFE1,51
09.07.2025 0:38:52
Indexy online
AD Index online
select
AD Index online
 

  • 07.07.2025
Genscript Biotech (Hong Kong)
Závěr k 7.7.2025 Změna (%) Změna (HKD) Objem obchodů (HKD)
14,64 -3,05 -0,46 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 09.07.2025
Popis společnosti
Obecné informace
Název společnostiGenscript Biotech Corp
Ticker1548
Kmenové akcie:Ordinary Shares
RIC1548.HK
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 5 568
Akcie v oběhu k 10.06.20252 178 855 282
MěnaUSD
Kontaktní informace
UliceNo. 28
MěstoNANJING
PSČ 
ZeměChina
Kontatní osoba 
Funkce kontaktní osoby 
Telefon862 558 897 288
Fax862558897288

Business Summary: Genscript Biotech Corp is a company primarily engaged in bioscience research and related businesses. The Company operates through four segments. The Life-Science Services and Products segment provides comprehensive reagent services and products, instruments and custom-tailored solutions for gene therapy, cell therapy, antibody therapeutics, vaccines and diagnostics. The Biologics Development Services segment provides comprehensive services aimed to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production by non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment is engaged in the discovery and development of novel cell therapies for oncology and other indications.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Genscript Biotech Corp revenues increased 6% to $594.5M. Net loss before extraordinary items totaled $67.2M vs. income of $422.5M. Revenues reflect United States of America segment increase of 5% to $265.1M, Europe segment increase of 17% to $80.9M. Net loss reflects Fair Value Adjustments on Other Assets increase from $129.2M (income) to $123.6M (expense).
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSOffices of All Other Miscellaneous Health Practitioners
NAICSOffices of Other Holding Companies
NAICS2007Research and Development in Biotechnology
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Offices of All Oth Misc Health Practitioners
NAICS2007Offices of Other Holding Companies
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Offices of All Other Miscellaneous Health Practitioners
NAICS1997Offices of Other Holding Companies
SICCommercial Physical Research
SICBiological Prod's Not Diagnostic
SICOffices Of Health Practices Nec
SICHolding Companies, Nec



  • Poslední aktualizace: 09.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardJiange Meng5622.11.2020
President, Co-Founder, Executive DirectorYe Wang5621.05.201521.05.2015
Chief Executive OfficerWeihui Shao4401.01.202308.07.2021
Chief Financial OfficerShiniu Wei4501.12.202001.12.2020
Executive DirectorFangliang Zhang6017.12.202221.05.2015
Executive Director, Chief Strategy OfficerLi Zhu7522.11.202001.01.2010
Company SecretaryWai Ling Wong-24.08.201524.08.2015